This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 2019 Aug 9;4(12):1748-1751.

doi: 10.1016/j.ekir.2019.07.022. eCollection 2019 Dec.

Elevated Fibroblast Growth Factor 23 Levels Are Associated With Greater Diastolic Dysfunction in ESRD

Shilpa Sharma^{1

2

3}, Mark R Hanudel⁴, Joachim H Ix^{5

6}, Isidro B Salusky⁴, Tomas Ganz^{3

7}, Kim-Lien Nguyen^{2

8}

Affiliations

Affiliations

¹ Division of Nephrology, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
² Veterans Affairs, Greater Los Angeles Healthcare System, Los Angeles, California, USA.
³ Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
⁴ Department of Pediatrics, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
⁵ Division of Nephrology-Hypertension, University of California San Diego, San Diego, California, USA.
⁶ Veterans Affairs, San Diego Healthcare System, San Diego, California, USA.
⁷ Department of Pathology, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
⁸ Division of Cardiology, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.

PMID: 31844812
PMCID: PMC6895593
DOI: 10.1016/j.ekir.2019.07.022

Elevated Fibroblast Growth Factor 23 Levels Are Associated With Greater Diastolic Dysfunction in ESRD

Shilpa Sharma et al. Kidney Int Rep. 2019.

. 2019 Aug 9;4(12):1748-1751.

doi: 10.1016/j.ekir.2019.07.022. eCollection 2019 Dec.

Authors

Shilpa Sharma^{1

2

3}, Mark R Hanudel⁴, Joachim H Ix^{5

6}, Isidro B Salusky⁴, Tomas Ganz^{3

7}, Kim-Lien Nguyen^{2

8}

Affiliations

¹ Division of Nephrology, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
² Veterans Affairs, Greater Los Angeles Healthcare System, Los Angeles, California, USA.
³ Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
⁴ Department of Pediatrics, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
⁵ Division of Nephrology-Hypertension, University of California San Diego, San Diego, California, USA.
⁶ Veterans Affairs, San Diego Healthcare System, San Diego, California, USA.
⁷ Department of Pathology, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
⁸ Division of Cardiology, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.

PMID: 31844812
PMCID: PMC6895593
DOI: 10.1016/j.ekir.2019.07.022

No abstract available

PubMed Disclaimer

Figures

Figure 1
Box plots showing the relationship between the grading of diastolic dysfunction and the natural logarithm of intact fibroblast growth factor 23 (FGF23) in 47 hemodialysis patients. Elevated levels of natural log–transformed intact FGF23 were significantly associated with a higher grade of left ventricular diastolic dysfunction (R² = 0.51; 95% confidence interval for slope, 1.7–3.4; P < 0.001).

See this image and copyright information in PMC

References

1. Cozzolino M., Mangano M., Stucchi A. Cardiovascular disease in dialysis patients. Nephrol Dial Transplant. 2018;33(suppl 3):iii28–iii34. - PMC - PubMed
1. Isakova T., Xie H., Yang W. Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA. 2011;305:2432–2439. - PMC - PubMed
1. Grabner A., Amaral A.P., Schramm K. Activation of cardiac fibroblast growth factor receptor 4 causes left ventricular hypertrophy. Cell Metab. 2015;22:1020–1032. - PMC - PubMed
1. Jovanovich A., Ix J.H., Gottdiener J. Fibroblast growth factor 23, left ventricular mass, and left ventricular hypertrophy in community-dwelling older adults. Atherosclerosis. 2013;231:114–119. - PMC - PubMed
1. Jovanovich A., You Z., Isakova T. Fibroblast growth factor 23 trajectories in chronic hemodialysis patients: lessons from the HEMO study. Am J Nephrol. 2019;49:263–270. - PMC - PubMed

Grants and funding

LinkOut - more resources

Full Text Sources